# CICC Qide

> CICC Qide is a VC fund backing Health Care, Biotechnology and Medical. See 18 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 18
- Last investment: May 2024
- Lead investor: 56%
- Last updated: Aug 2026

CICC Qide is an investment management firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 61% |
| Biotechnology | 9 | 50% |
| Medical | 7 | 39% |
| Biopharma | 5 | 28% |
| Pharmaceutical | 4 | 22% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 8 | 44% |
| Series A | 2 | 11% |
| Series C | 2 | 11% |
| Series D | 2 | 11% |
| Seed | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 15 | 83% |
| United States | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Synaura | Synaura manufactures, supplies, and develops human milk oligosaccharides (HMO) for breastfed infants. The company specializes in biosynthesis technology and provides baby formula that has the same nutritional value as breast milk, allowing customers to use HMO products. | $13.9M | Seed | May 09, 2024 |  |
| ICE Bioscience | ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | $14.2M | Series B | Aug 03, 2023 |  |
| Care Medical | Care Medical is a membrane science platform that focuses on blood purification and biopharmaceuticals. |  | Series C | Jun 14, 2023 |  |
| Yi'an Holdings | Yi'an Holdings is a financial services company that provides one-stop investment banking services to small and medium-sized companies. | $11.9M | Series A | Jan 30, 2023 |  |
| Yaohai Bio | Yaohai Biotechnology Co., Ltd. is a genetic engineering protein drug developer, dedicated to contracting services for biotechnology products, and building an open, all-round, integrated production and research service platform for biological products CRO/CMO/MAH. | $14M | Series B | Nov 21, 2022 |  |
| ICE Bioscience | ICE Bioscience was founded in 2010, an Innovative CRO+ Explorer company focusing in early drug discovery services from target validation to pre-clinical candidate identification, with strong capabilities and technologies in Immunology and Oncology, Cardiovascular and CNS diseases areas. ICE Bioscience provides high professional communication andflexible collaboration models, to speed up drug discovery process better and faster.ICE Bioscience has wide target-based panel screening platform ready-to-use, we keep trying to expand diverse techniques related to Biology and Pharmacology, to support various drug discovery purpose for different indications and clinical needs, we do have quite a lot of new assays development experience and passion, to accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. | $14M | Series B | Sep 26, 2022 |  |
| AMCARELAB | AMCARELAB includes three major disciplines : clinical cytogenetics, Clinical Biochemistry, and Clinical Molecular Genetics. | $29.9M | Series B | Jun 09, 2022 |  |
| CytoNiche | CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated andintelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products. | $47.5M | Series B | Mar 03, 2022 |  |
| CytoNiche | CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated andintelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products. | $47.5M | Series B | Mar 03, 2022 |  |
| Bo Shengji | Bo Shengji is a biotech company that develops tumor cell immunotherapy technology and products for anti-cancer drugs, kits, etc. |  | Series B | Jan 10, 2022 |  |

10 of 18 investments shown.

## Co-investors
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 4 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 2 deals together
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 2 deals together
- [Aibo Qingshi Venture Capital Fund](https://shizune.co/investors/profile/aibo-qingshi-venture-capital-fund) — VC Fund, 2 deals together
- [Hongtai Capital Holdings](https://shizune.co/investors/profile/aplus-capital) — VC Fund, 2 deals together
- [Bencao Capital](https://shizune.co/investors/profile/bencao-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does CICC Qide invest in?

CICC Qide invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did CICC Qide last invest?

The most recent investment recorded for CICC Qide closed in May 2024. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co